UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out

Cancer treatment reviews, 2019-05, Vol.75, p.39-51

2019

Volltextzugriff (PDF)

Targeted therapy-induced diarrhea: A review of the literature

Critical reviews in oncology/hematology, 2014-05, Vol.90 (2), p.165-179

2014

Volltextzugriff (PDF)

9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results

European journal of cancer (1990), 2011, Vol.47, p.S596-S596

2011

Volltextzugriff (PDF)

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients

European journal of cancer (1990), 1999-02, Vol.35 (2), p.208-213

1999

Volltextzugriff (PDF)

Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients

The Journal of steroid biochemistry and molecular biology, 2002-04, Vol.80 (4), p.411-418

2002

Volltextzugriff (PDF)

The minimal effective exemestane dose for endocrine activity in advanced breast cancer

European journal of cancer (1990), 1997-04, Vol.33 (4), p.587-591

1997

Volltextzugriff (PDF)

c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients

Breast (Edinburgh), 2002-08, Vol.11 (4), p.286-294

2002

Volltextzugriff (PDF)

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

European journal of cancer (1990), 1995-12, Vol.31 (13), p.2426-2427

1995

Volltextzugriff (PDF)

Steroidal aromatase inhibitors in elderly patients

Critical reviews in oncology/hematology, 2000-02, Vol.33 (2), p.137-142

2000

Volltextzugriff (PDF)

Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2004-02, Vol.43 (2), p.203-208

2004

Volltextzugriff (PDF)

The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients

Biomedicine & pharmacotherapy, 2004-05, Vol.58 (4), p.255-259

2004

Volltextzugriff (PDF)

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

The Journal of steroid biochemistry and molecular biology, 1997-11, Vol.63 (4), p.261-267

1997

Volltextzugriff (PDF)

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

The Journal of steroid biochemistry and molecular biology, 2000-12, Vol.75 (1), p.65-73

2000

Volltextzugriff (PDF)

Safety and activity of Capecitabine in elderly patients with advanced breast cancer

European journal of cancer (1990), 2001-04, Vol.37, p.S197-S197

2001

Volltextzugriff (PDF)

Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: Short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA)

European journal of cancer (1990), 2001-04, Vol.37, p.S193-S194

2001

Volltextzugriff (PDF)

Insulin-like growth factor (IGF) components in postmenopausal metastatic breast cancer (MBC) patient having progressed on tamoxifen: different effect of exemestane (EXE) or megestrol acetate (MA)

European journal of cancer (1990), 2001-04, Vol.37, p.S192-S192

2001

Volltextzugriff (PDF)

Biological study of anastrozole in post-menopausal advanced breast cancer (ABC) patients: Effects on bone metabolism and oestrogen suppression

European journal of cancer (1990), 2001-04, Vol.37, p.S197-S197

2001

Volltextzugriff (PDF)

The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group

European journal of cancer (1990), 1997-09, Vol.33, p.S155-S155

1997

Volltextzugriff (PDF)

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1

European journal of cancer (1990), 1999-02, Vol.35 (2), p.208-213

1999

Volltextzugriff (PDF)

Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy

Cancer treatment reviews, 1993-04, Vol.19, p.31-36

1993

Volltextzugriff (PDF)

963 Exemestane in postmenopausal patients with advanced breast cancer: A dose-finding study

European journal of cancer (1990), 1995-11, Vol.31, p.S200-S200

1995

Volltextzugriff (PDF)

Hormone therapy in advanced breast carcinoma: present and future trends

Cancer treatment reviews, 1994-07, Vol.20 (3), p.241-258

1994

Volltextzugriff (PDF)

4-Hydroxyandrostenedione (4-OHA) as first line treatment in postmenopausal patients with advanced breast cancer(ABC)

European journal of cancer (1990), 1993, Vol.29, p.S77-S77

1993

Volltextzugriff (PDF)

A randomized study with 4-hydroxyandrostenedione (4-OHA) in postmenopausal advanced breast cancer (ABC): Characteristics of responsive patients

Breast (Edinburgh), 1992-09, Vol.1 (3), p.160-160

1992

Volltextzugriff (PDF)

Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma

European journal of cancer (1990), 1992, Vol.28 (10), p.1719-1720

Biological Response Modifiers in Melanoma (BREMIM) italian Cooperative Group

1992

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(25)
Tagungsberichte
(1)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(12)
Oncology
(11)
Biological And Medical Sciences
(10)
Female
(10)
Medical Sciences
(10)
Aged
(9)
Chemotherapy
(9)
Middle Aged
(9)
Pharmacology. Drug Treatments
(9)
Aromatase Inhibitors
(8)
Antineoplastic Agents
(7)
Breast Neoplasms - Drug Therapy
(7)
Adult
(5)
Postmenopause
(5)
Aged, 80 And Over
(4)
Androstenedione - Analogs & Derivatives
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Breast Cancer
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta.com
(26)
Elsevier ScienceDirect Journals Complete
(26)
MEDLINE
(12)
The Electronic Journals Library
(3)
IngentaConnect Journals
(1)

Zeitschrift / Serie

European Journal Of Cancer
(13)
Cancer Treatment Reviews
(3)
The Journal Of Steroid Biochemistry And Molecular Biology
(3)
Breast
(2)
Critical Reviews In Oncology/hematology
(2)
Biomedicine & Pharmacotherapy
(1)
Lung Cancer
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out

Targeted therapy-induced diarrhea: A review of the literature

9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients

Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients

The minimal effective exemestane dose for endocrine activity in advanced breast cancer

c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

Steroidal aromatase inhibitors in elderly patients

Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer

The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

Safety and activity of Capecitabine in elderly patients with advanced breast cancer

Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: Short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA)

Insulin-like growth factor (IGF) components in postmenopausal metastatic breast cancer (MBC) patient having progressed on tamoxifen: different effect of exemestane (EXE) or megestrol acetate (MA)

Biological study of anastrozole in post-menopausal advanced breast cancer (ABC) patients: Effects on bone metabolism and oestrogen suppression

The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1

Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy

963 Exemestane in postmenopausal patients with advanced breast cancer: A dose-finding study

Hormone therapy in advanced breast carcinoma: present and future trends

4-Hydroxyandrostenedione (4-OHA) as first line treatment in postmenopausal patients with advanced breast cancer(ABC)

A randomized study with 4-hydroxyandrostenedione (4-OHA) in postmenopausal advanced breast cancer (ABC): Characteristics of responsive patients

Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma

Aktive Filter

Suchergebnisse filtern